Covid-19 has resurged, claiming two lives in the early months of the new year. Bangladesh has identified a COVID-19 sub-variant for the first time. JN.1, identified as a sub-variant, is categorized as a "variant of interest" by the World Health Organization (WHO) within the omicron strain. JN.1 was initially identified in Canada on October 9, last year and its prevalence has since escalated swiftly. It is once again becoming a prominent topic in the headlines of the countrys newspapers. Bangladesh may face new challenges, and if thats the case, heightened awareness will be necessary.
The first case of Covid-19 in Bangladesh was reported on March 8, 2020 and the first death occurred on March 18 of the same year. Since the confirmation of the first Covid-19 cases in Bangladesh, the country has witnessed the loss of nearly 30,000 lives, with over 2 million people, out of a population of 170 million, being infected by the corona virus. Four years ago, the world was engulfed by the SARS-CoV-2 corona virus pandemic. Since then, various strains of the virus have emerged, each with varying degrees of impact. Some were more potent than others, leading to a significant loss of lives.
Health experts state that there is currently no knowledge regarding whether infections with JN.1 result in distinct symptoms compared to other variants. As outlined by the government, the common symptoms of COVID-19 include: Fever or chills, cough, shortness of breath, fatigue, muscle or body aches, headache, sore throat and runny nose.
As the spike protein, which existing vaccines are designed to target, is also present in JN.1 and other lineages of BA.2.86, current vaccines are expected to be effective against these variants and mentioned that preliminary evidence suggests the XBB recombinant vaccine provides protection against JN.1 as well, according to infectious disease specialists.
Recently, the Directorate General of Health Services (DGHS) advised the public to wear masks in crowded places, practice frequent handwashing, and receive the second booster dose of the Covid-19 vaccine. Vaccines are being distributed by the DGHS following approval from the technical committee and the World Health Organization (WHO), along with the letter from the manufacturing company. The Directorate General of Health Services (DGHS) has initiated the administration of the third and fourth doses of COVID-19 vaccinations in response to resurgence in the countrys coronavirus infection rate. Commencing on Monday, the vaccination campaign is underway at nine centers in Dhaka. In a directive issued on Thursday, the DGHS urged everyone to receive booster doses for added protection against the virus.
Given the ongoing challenges posed by dengue and the onset of the cold season affecting our healthcare system, it is imperative that we remain vigilant and prevent any further impact from a new variant of the corona virus.
The government may enhance surveillance efforts to closely monitor the spread of the JN.1 variant. Increased testing and efficient contact tracing will be crucial to identify and isolate cases promptly. The government is likely to launch public awareness campaigns to inform citizens about the presence of the new variant, its characteristics, and the importance of adhering to safety measures. Clear communication will be essential to ensure that the public is well-informed and takes necessary precautions. Accelerating vaccination efforts will be a priority. The government may focus on expanding vaccination campaigns to ensure a larger portion of the population is protected against severe outcomes, including those associated with new variants. Collaboration with international health organizations and neighboring countries may be intensified to share information, resources, and strategies for dealing with the new variant.
Alongside the various measures implemented by the government, it is crucial for people to remain vigilant.
Heightened awareness and completing the vaccine dosage constitute an appropriate response.
The writer is a journalist, The Bangladesh Today
